Antibody Production Market Snapshot

“The antibody production market is expected to grow at 13.14% CAGR from 2023 to 2030. It is predictable to reach above USD 24.09 billion by 2030 from USD 8.45 billion in 2022.”

The immune system uses antibodies, often referred to as immunoglobulins, which are giant Y-shaped proteins generated by plasma cells, to neutralize invaders including bacteria and viruses. When the body is invaded by foreign substances called antigens, the immune system responds by producing antibodies. Monoclonal and polyclonal antibodies, which can be created via hybridoma- and hybridoma-free procedures, are the two main forms of antibodies. The global antibody production market is expanding as a result of rising targeted immunotherapy use, an improvement in the rate at which therapeutic antibodies are approved by regulatory bodies, and an increase in R&D spending by pharmaceutical and biotechnology firms. In addition, the prevalence of infectious diseases is rising, as is the demand for protein treatments.

The market is also being driven by increased initiatives for discovering and developing new antibiotics, an increase in contagious and bacterial infections, and greater funding to speed up the development of novel antibiotics for infectious diseases. Additionally, antibiotics are frequently employed in the production of bacterial and viral vaccines to prevent contamination, which is anticipated to accelerate the growth of the market's revenue. However, the high price of primary antibodies limits market expansion. Opportunities for the market are anticipated to arise from an increase in R&D efforts for the creation of sophisticated antibodies and the expansion of targeted immunotherapy use. The market for antibody manufacturing is primarily driven by research conducted by the biopharmaceutical sector and academic organizations. In order to investigate biological processes, comprehend disease mechanisms, and create new therapies, antibodies are essential tools. The need for antibodies is fueled in part by the ongoing growth of research initiatives and partnerships.

Due to reasons such as the increased frequency of chronic and infectious diseases, the rising use of targeted medicines, developments in biotechnology and genomics, and the rising demand for diagnostic applications, the global market for antibody production is expanding significantly. A favorable regulatory environment, increased investment in the biotechnology and pharmaceutical sectors, expanded research activities in academia and business, and technological developments in antibody production further contribute to the expansion. These elements contribute to the increase in demand for antibodies across a range of fields, such as medicines, diagnostics, and scientific inquiry. As the demand for precise and personalized treatments, illness monitoring, and precise diagnostics continues to rise globally, the market is anticipated to continue expanding.

>>>Download Sample Report Now: https://marketreportservice.com/request-sample/antibody-production-market-54565 

Growth Drivers

The rise in chronic diseases and an aging population are expected to drive market expansion in the coming years. The World Health Organization predicts a 60% increase in cancer cases over the next two decades, putting significant strain on healthcare systems, individuals, and communities. By 2040, there will be 30 million more cancer cases worldwide. This growth will necessitate increased manufacturing capacity and research operations for innovation, driving market expansion in the healthcare sector.

Restraints

Purifying antibodies from complex combinations is a complex and time-consuming process, requiring labor-intensive and expensive processes. High purity criteria and impurity removal can result in labor-intensive and expensive synthesis. Specialized equipment, cell culture conditions, and purification processes make antibody synthesis costly, particularly for therapeutic applications. This may limit the availability of antibody-based therapeutics, potentially restraining market growth.

Opportunity

The increasing approvals of monoclonal antibodies by the FDA are expected to drive market expansion. For instance, EPKINLYTM was authorized in May 2023 for treating adult patients with diffuse large B-cell lymphoma. The increasing prevalence of communicable and noncommunicable diseases has prompted the FDA and other agencies to expedite the approval of monoclonal antibodies for research and development, thereby driving market expansion.

Segment Analysis

Based on product type, a significant portion of the market was made up of polyclonal antibodies. Animals, often rabbits, goats, or mice, are immunized with an antigen to produce polyclonal antibodies. A variety of antibodies directed at various antigen epitopes are produced by these animals. Comparatively, to monoclonal antibodies, polyclonal antibodies can recognize several epitopes on the target antigen, enabling a broader target recognition. They can thus be used for a variety of purposes, such as research, diagnostics, and treatment. Animal immunization can be used to develop polyclonal antibodies fast and economically. This procedure does not call for intensive cell culture methods or cloning, such as those used in the creation of monoclonal antibodies. While monoclonal antibodies created in a lab aid in boosting your immune system. The term "monoclonal" designates the clonal nature of the laboratory-made antibodies. These antibodies are perfect replicas of one another. For murine antibodies, the letters "mab" are frequently added at the end of the product names that are generic. an antibody created in a lab by fusing a little amount of a monoclonal mouse or rat antibody with a human antibody. The target antigen is bound to by the mouse or rat portion of the antibody and is protected from immune system attack by the human portion. Chimeric antibodies are proteins that contain domains from many species. For instance, human or (any other species') antibodies may be used to substitute the Fc region or all of the constant sections of a mouse monoclonal antibody (mAb). Antibodies from non-human organisms that have had their protein sequences altered to make them more comparable to antibody variations made in humans naturally are referred to as humanized antibodies. Typically, monoclonal antibodies created for human administration (such as those created as anti-cancer medications) are subjected to the "humanization" procedure. When creating a specific antibody requires the use of a non-human immune system (like that of a mouse), humanization may be required.

Based on end use, a significant portion of the market was made up of pharmaceutical and biotechnology companies. Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Research Institutes are the end-use industries of the antibody production market. Diagnostic Laboratories anticipated the largest segment for antibody production on the basis of end-user. Companies involved in biotechnology and pharmaceuticals make significant investments in the study and creation of therapeutic antibodies. Particularly monoclonal antibodies are used in the creation of antibody-based treatments for a variety of illnesses, including cancer, autoimmune conditions, and infectious diseases. To assess the safety and effectiveness of therapeutic antibodies, these businesses conduct rigorous preclinical and clinical research. The establishment of internal antibody manufacturing facilities by numerous pharmaceutical and biotechnology businesses has allowed them to create antibodies for their own internal research and development purposes. This makes it possible to have more control over the antibodies' intellectual property, supply, and quality.

Key Companies Profiled           

The market research report covers the analysis of market players. Key companies profiled in the report include Thermo Fisher Scientific, Merck KGaA, Abcam, Bio-Rad Laboratories, GenScript Biotech Corporation, Lonza Group, Rockland Immunochemicals, GenHunter Corporation, Cell Signaling Technology, Novus Biologicals.

New Developments

26 May 2023: The partnership between Thermo Fisher Scientific and BRIN strengthened research infrastructure and capabilities in Indonesia.

9 May 2023: Thermo Fisher Scientific and Pfizer partnered to expand localized access to next-generation sequencing-based testing for cancer patients in international markets.

Antibody Production Market Regional Analysis

With a market revenue share of more than 40% in 2022, the North American region held the top spot. Due to a number of factors, such as an increase in the geriatric population, higher healthcare spending, ongoing growth in R&D activities, and an increase in the use of these therapeutic applications in the treatment of various disorders like PCOS (polycystic ovary syndrome) and breast cancer in the U.S., North America is anticipated to account for the largest revenue share in the global market during the forecast period.  For instance, a Centers for Disease Control and Prevention (CDC) report found that PCOS affects 6% to 12% of women or more than 5 million women of reproductive age. It is one of the most common causes of female infertility in the U.S., which is what is causing the market to grow. Furthermore, the presence of sophisticated health infrastructure and well-established direct compensation regulations are anticipated to significantly boost market revenue growth throughout the course of the projection year.

Segments Covered in Antibody Production Market

Antibody Production Market by Product Type,

• Polyclonal Antibody
• Monoclonal Antibody
• Murine
• Chimeric
• Humanized

Antibody Production Market by End Use

• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• Research Institutes

Antibody Production Market by Region

• North America
• Asia Pacific
• Europe
• South America
• Middle East and Africa

Frequently Asked Questions

What is the worth of the antibody production market?

antibody production market is expected to grow at 13.14% CAGR from 2023 to 2030. It is predictable to reach above USD 24.09 billion by 2030 from USD 8.45 billion in 2022.

What is the size of North America in the antibody production market?

North America held more than 40% of the antibody production market revenue share in 2022 and will witness expansion in the forecast period.

What are some of the antibody production market's driving forces?

The demand for antibodies is being driven by the rise in chronic illnesses like cancer, autoimmune conditions, cardiovascular diseases, and infectious diseases. In the medical field, antibodies are indispensable tools due to they play a critical role in illness diagnosis, monitoring, and targeted therapy.

Which are the top companies to hold the market share in the antibody production market?

The market research report covers the analysis of market players. Key companies profiled in the report include Thermo Fisher Scientific, Merck KGaA, Abcam, Bio-Rad Laboratories, GenScript Biotech Corporation, Lonza Group, Rockland Immunochemicals, GenHunter Corporation, Cell Signaling Technology, Novus Biologicals.

Which is the largest regional market for antibody production market?

Due to the concentration of several sizable biotech and biopharmaceutical companies in the region, North America accounts for a sizable portion of the industry. Globally, improvements in the healthcare and research sectors as well as an increasing emphasis on drug discovery in North America are all assisting in the regional market's growth.